An HTLV-I Vaccine: Why, How, for Whom?

AIDS Research and Human Retroviruses

Volumn 9, Issue 5, 1993, Pages 381-386

  de The G ^a   Bomford, R ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGENIC VARIATION; CANCER RISK; CENTRAL AMERICA; DISEASE COURSE; DRUG ABUSE; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; NEUROLOGY; ONCOLOGY; REVIEW; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA; UNITED STATES;

ADULT; AIDS VACCINES; ANIMAL; DISEASE MODELS, ANIMAL; FEMALE; HTLV-I INFECTIONS; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; PREGNANCY; SUPPORT, NON-U.S. GOV'T; VIRAL VACCINES;

EID: 0027156506     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1993.9.381     Document Type: Article

References (70)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, and Gallo RC: Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Nati Acad Sci USA 1980;77:7415–7419.
2. Tajima K, and the T- and B-cell malignancy study group and coauthors: The 4th nation-wide study of adult T-cell leukemia/ lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. Int J Cancer 1990;45:237–243.
3. Mueller N: The epidemiology of HTLV-I infection. Cancer Causes Control Pap Symp 1991;2:37–52.
4. Murphey EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, and Blattner WA: Modelling the risk of ATLL in persons infected with HTLV-I. Int J Cancer 1989;43:250–253.
5. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, Khabbaz RF, and Janssen RS: The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 1990;3:1096–1101.
6. Gessain A and Gout O: Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992; 117:933–946.
7. Meytes D, Schochat B, Lee H, Nadel G, Sidi Y, Cemey M, Swanson P, Shaklai M, Kilim Y, and Elgat M: Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. Lancet 1990;336:1533–1535.
8. Denic S, Nolan P, Doherty J, Garson J, Tuke P, and Tedder R: HTLV-I infection in Iraq. Lancet 1990;336:1135–1136.
9. Safai B, Farid R, Peralta H, and Raafat J: Preliminary studies of HTLV-I in Iran. Proc 5th Int Conf Human Retrovirology, Kumamoto, Japan, 1992.
10. Gessain A, Yanagihara R, Franchini G, Garnito RM, Jenkins CL, Ajdukiewicz AB, Gallo RC, and Gajdusek DC: Highly divergent molecular variants of human T-lymphotropic virus type I from isolated populations in Papua New Guinea and the Solomon Islands. Proc Nati Acad Sci USA 1991;88:7694–7698.
11. Sherman MP, Saksena NK, Dube DK, Yanagihara R, and Poiesz BJ: Evolutionary insights on the origin of human T-cell lymphoma/ leukemia virus type I (HTLV-1) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea. J Virol 1992; 66:2556–2563.
12. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, and Chen ISY: High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989;244:471–475.
13. Ehrlich GD, Glaser JB, LaVigne K, Quan D, Mildvan D, Sninsky JJ, Kwok S, Papsidero L, and Poiesz B: Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction. Blood 1989;74:1658–1664.
14. Kwok S, Gallo D, Hanson C, McKinney N, Poiesz B, and Sninsky JJ: High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing. AIDS Res Hum Retroviruses 1990;6:561–565.
15. Biggar RJ, Buskell-Bales Z, Yakshe PN, Caussy D, Gridley G, and Seeff L: Antibody to human retroviruses among drug users in three east coast American cities, 1972–1976. J Infect Dis 1991; 163: 57–63.
16. Khabbaz RF, Onorato ID, Cannon RO, Hartley TM, Roberts B, Hosein B, and Kaplan JE: Seroprevalence of HTLV-1 and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. New Engl J Med 1992;326:375–380.
17. Zella D, Mori L, Sala M, Ferrante P, Casoli C, Magnani G, Achilli G, Cattaneo E, Lori F, and Bertazzoni U: HTLV-II infection in Italian drug abusers. Lancet 1990;336:575–576.
18. Varnier OE, Lillo F, Alexander SS, Forbis RM, Present W, and Lazzarin A: HTLV seropositivity in Italian intravenous drug addicts is primarily due to HTLV-II infection. JAMA 1991;265:597.
19. Gessain A, Barin F, Vernant JC.Gout O, Maurs L, Calendar A, and De Thé G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;(ii):407–410.
20. Roman GC, Roman LN, and Osame M: Human T lyphotropic virus type I neurotropism. Prog Med Virol 1990;37:190–210.
21. Vernant JC, Bûcher B, Buisson G, Beilance R. Grolier-Bois L, Francois MA, and Smadja D: Clinical spectrum of non-haemato-logical HTLV-I infection in Martinique. Proc 5th Int Conf Human Retrovirology, Kumamoto, Japan, 1992.
22. Murai K, Tachibana N, Shioiri S, Shishime E, Okayama A, Ishizaki J, Tsuda K, and Mueller N: Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J Acquir Immune Defic Syndr 1990;3:1006–1009.
23. Morgan O, Rodgers-Johnson P, Mora C, and Char G: HTLV-I and polymyositis in Jamaica. Lancet 1989;(ii):1184–1186.
24. Ijichi S, Matsuda T, Maruyama I, Izumihara T, Kojima K, Niimura T, Maruyama Y, Sonoda S, Yoshida A, and Osame M: Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann Rheum Dis 1990;49:718–721.
25. Lagrenade L, Hanchard B, Fletcher V, Cranston B, and Blattner W: Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet 1990;336:1345–1347.
26. Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Shirao M, Nakashima S, Mori S, Araki S, and Miyata N: HTLV-1 uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992;83:236–239.
27. Bartholomew C, Blattner W, and Cleghorn F: Progression to AIDS in homosexual men co-infected with HIV and HTLV-I in Trinidad. Lancet 1987;(ii):1469.
28. Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, and Fletcher MA: HTLV I/II seropositivity and death from AIDS among HIV-I seropositive intravenous drug users. Lancet 1990;335:1439–1441.
29. Hino S: Maternal-infant transmission of HTLV-I: implication for disease. In: Human Retrovirology: HTLV. WA Blattner (ed.). Raven Press, New York, 1990, pp. 363–375.
30. Ichimaru M, Ikeda S, Kinoshita K, Hino S, and Tsuji Y: Mother-to-child transmission of HTLV-I. Cancer Detect Prev 1991; 15:177–181.
31. Okochi K, Sato H, and Hinuma Y: A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984;46:245–253.
32. Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Homura H, and Okochi K: Intra-familial transmission of adult T cell leukemia virus. J Infect Dis 1986;154:851–857.
33. Miyoshi I, Yoshimoto S, Kubonishi I, Fujishita M, Ohtsuki Y, Yamashita M, Yamato K, Hirose S, Taguchi H, Niiya K, and Kobayashi M: Infectious transmission of human T-cell leukemia virus to rabbits. Int J Cancer 1985;35:81–85.
34. Suga T, Kameyama T, Kinoshita T, Shimotohno K, Matsumura M, Tanaka H, Kushida S, Ami Y, Uchida M, Uchida K, and Miwa M: Infection of rats with HTLV-I: A small animal model for HTLV-I carriers. Int J Cancer 1991;49:764–769.
35. Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, Ito Y, Hatanaka M, Hinuma Y, Sugimoto M, Takahashi-Nishimaki F, Maruyama T, Miki K, Suzuki K, Morita M, Sashiyama H, and Hayami M: Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 1987;6: 3379–3384.
36. Kataoka R, Takehara N, Iwahara Y, Sawada T, Ohtsuki Y, Dawei Y, Hoshino H, and Miyoshi I: Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990;76:1657–1661.
37. Sawada T, Iwahara Y, Ishii K, Taguchi H, Hoshino H, and Miyoshi I: Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J Infect Dis 1991;164:1193–1196.
38. Takahashi K, Takezaki T, Oki T, Kawakami K, Yashiki S, Fujiyoshi T, Usuku K, Mueller N, The Mother-to-Child Transmission Study Group, Osame M, Miyata K, Nagata Y, and Sonoda S: Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type. 1. Int J Cancer 1991;49:673–677.
39. Yamamoto N, Hayami M, Komuro A, Schneider J, Hunsmann G, Okada M, and Hinuma Y: Experimental infection of cynomolgus monkeys with a human retrovirus, adult T-cell leukemia virus. Med Microbiol 1984;173:57–64.
40. Seto A, Isono T, and Ogawa K: Infection of inbred rabbits with cell-free HTLV-I. Leuk Res 1991;15:105–110.
41. Nakamura H, Hayami M, Ohta Y, Ishikawa K, Tsujimoto H, Kiyokawa T, Yoshida M, Sasagawa A, and Honjo S: Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer 1987;40:403–407.
42. Gray GS, White M, Bartman T, and Mann D: Envelope gene sequence of HTLV-I isolate MT-2 and its comparison with other HTLV-1 isolates. Virology 1990;177:391–395.
43. Komurian F, Pelloquin F, and De Thé G: In vivo genomic variability of HTLV-I depends more upon geography than pathologies. J Virol 1991;65:3770–3778.
44. Schulz TF, Calabro M-L, Hoad JG, Carrington CVF, Matutes E, Catovsky D, and Weiss RA: HTLV-I envelope sequences from Brazil, the Caribbean, and Romania: clustering of sequences according to geographic origin and variability in an antigenic epitope. Virology 1991;184:483–491.
45. Clapham P, Nagy K, and Weiss RA: Pseudotypes of human T-cell leukemia virus types I and II: neutralisation by patients' sera. Proc Nati Acad Sci USA 1984;81:2886–2889.
46. Hoshino H, Clapham PR, Weiss RA, Miyoshi I, Yoshida M, and Miwa M: Human T-cell leukemia virus type I: pseudotype neutralisation of Japanese and American isolates with human and rabbit sera. Int J Cancer 1985;36:671–675.
47. Bomford R: Adjuvants for viral vaccines. Rev Med Virol 1992;2:169–174.
48. Bomford R, Andronova T, McKnight A, Stapleton M, and Winsor S: The control of the antibody isotype response to HIV gpl20 by adjuvants. AIDS Res Hum Retroviruses 1992;8:1765–1771.
49. Osterhaus A, Weijer K, Uytdehaag F, Jarrett O, Sundquist B, and Morein B: Induction of protective immune response in cats by vaccination with feline leukemia virus ISCOM. J Immunol 1985;135:591–596.
50. Marciani DJ, Kensil CR, Beltz GA, Hung C, Cronier J, and Aubert A: Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 1991;9:89–96.
51. Rose CSP and Evans DJ: Poliovirus antigen chimeras. Trends Biotechnol 1991;9:415–421.
52. Tanaka Y, Zeng L, Shiraki H, Shida H, and Tozawa H: Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type 1 and induction of neutralizing antibody by peptide immunization. J Immunol 1991;147:354–360.
53. Kuroki M, Nakamura M, Itoyama Y, Tanaka Y, Shiraki H, Baba E, Esaki T, Tatsumoto T, Nagafuchi S, Nakano S, and Niho J: Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type I. J Immunol 1992;149:940–948.
54. Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, McAdams MW, McKnight A, Clapham PR, Weiss RA, and Haynes BF: Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J Virol 1992;66:5879–5889.
55. Graham FL: Adenoviruses as expression vectors and recombinant vaccines. Trends Biotechnol 1990;8:85–87.
56. Portetelle D, Limbach K, Burny A, Mammerickx M, Desmettre P, Riviere M, Zavada J, and Paoletti E: Recombinant vaccinia virus expression of the bovine leukemia virus envelope gene and protection of immunized sheep against infection. Vaccine 1991;9:194–200.
57. Paoletti E: Poxvirus recombinant vaccines. Ann NY Acad Sci 1990;590:309–325.
58. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, and Plotkin S: Immunization with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429–1432.
59. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, and Bloom BR: New use of BCG for recombinant vaccines. Nature (London) 1991;351:456–460.
60. Tanaka Y, Tozawa H, Koyanagi Y, and Shida H: Recognition of human T cell leukemia virus type I (HTLV-I) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. J Immunol 1990; 144:4202–4211.
61. Noguchi Y, Tateno M, Kondo N, Yoshiki T, Shida H, Nakayama E, and Shiku H: Rat cytotoxic T lymphocytes against human T-lymphotropic virus type I-infected cells recognize gag and env gene encoded antigens. J Immunol 1989;143:3737–3742.
62. Jacobson S, Shida H, McFarlin DE, Fauci AS, and Koenig S: Circulating CD8+ cytotoxic T lyphocytes specific for HTLV-I pX in patients with HTLV-I-associated neurological disease. Nature (London) 1990;348:245–248.
63. Parker CE, Daenke S, Nightingale S, and Bangham CRM: Activated, HTLV-I-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 1992;188:628–636.
64. Miyazawa M, Nishio J, and Chesebro B: Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J Virol 1992;66:4497–4507.
65. Lairmore MD, Jacobson S, Gracia F, De BK, Castillo L, Larreategui M, Roberts BD, Levine PH, Blattner WA, and Kaplan JE: Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Nati Acad Sei USA 1990;87:8840–8844.
66. Gessain A, Fretz C, Koulibaly M, Boudret M-L, Bah A, Raphael M, De Thé G, and Fournel J-J: Evidence of HTLV-II infection in Guinea, West Africa. J Acqu Imm Def Syndr 1993;6:323–328.
67. Goubau P, Desmyter J, Ghesquiere J, and Kasereka B: HTLV-11 among pygmies. Nature (London) 1992;359:201.
68. Kalyanaraman V, Sarngadharan M, Robert-Guroff M, Miyoshi I, Blayney D, Golde D, and Gallo R: A new subtype of human T-cell leukemia virus (HTLV-2) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571–573.
69. Rosenblatt JD, Plaeger-Marshall S, Giorgi JV, Swanson P, Chen IS, Chin E, Wang HJ, Canavaggio M, Black AC, and Lee H: A clinical, hématologie, and immunologie analysis of 21 HTLV-II-infected intravenous drug users. Blood 1990;76:409–417.
70. Hall WW, Takahashi H, Liv C, Kaplan MH, Scheewind O, Ijichi S, Nagashima K, and Gallo RC: Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol 1992;66:2456–2463.